Baseline demographic and treatment data for all patients, and for patients assessed to be in remission according to DAS28–CRP, SDAI, CDAI and ACR/EULAR at baseline
| All patients with radiographs n=535 | DAS28–CRP, baseline remission n=106 | SDAI baseline remission n= 37 | CDAI baseline remission n= 26 | ACR/EULAR criteria baseline remission n=30 | |
|---|---|---|---|---|---|
| Median (IQR) age | 59 (50, 67) | 54 (43, 61) | 52 (41, 58) | 49 (36, 61) | 55 (41, 61) |
| Median (IQR) disease duration | 11 (4, 23) | 7 (3, 17) | 6 (2, 11) | 6 (2, 16) | 6 (2, 11) |
| Female, n (%) | 442 (83) | 95 (90) | 34 (92) | 23 (89) | 27 (90) |
| RF positivity, n (%) | 339 (63) | 60 (57) | 19 (51) | 13 (50) | 15 (50) |
| Anti-CCP positivity, n (%) | 359 (67) | 67 (63) | 17 (46) | 13 (50) | 14 (47) |
| Sharp erosion score, median (IQR)/mean (SD) | 17 (3, 52)/33 (39) | 6 (1, 31)/21 (32) | 2 (0, 17)/13 (22) | 3 (0, 24)/15 (25) | 3 (0, 13)/12 (21) |
| Sharp joint space narrowing score, median (IQR)/mean (SD) | 7 (0, 33)/21 (28) | 1 (0, 16)/13 (23) | 0 (0, 4)/8 (17) | 0 (0, 6)/8 (18) | 1 (0, 3)/7 (17) |
| Total Sharp score, median (IQR)/mean (SD) | 25 (4, 82)/54 (64) | 8 (1, 47)/34 (52) | 2 (0, 36)/21 (38) | 2.5 (0, 44)/22 (40) | 5 (1, 23)/19 (37) |
| Treatment (categories not mutually exclusive) | |||||
| Glucocorticoids, n (%) | 177 (33) | 20 (19) | 7 (19) | 4 (15) | 3 (10) |
| Methotrexate, n (%) | 258 (48) | 54 (51) | 17 (46) | 10 (39) | 14 (47) |
| Hydroxychloroquine, n (%) | 92 (17) | 29 (27) | 7 (19) | 5 (19) | 7 (23) |
| Other synthetic DMARD, n (%) | 94 (18) | 16 (15) | 3 (8) | 3 (12) | 3 (10) |
| Biological DMARD, n (%) | 205 (38) | 45 (43) | 21 (57) | 13 (50) | 14 (47) |
ACR, American College of Rheumatology; Anti-CCP, anticyclic citrullinated peptide antibody; CDAI, clinical disease activity index; CRP, C-reactive protein; DAS28–CRP, disease activity score based on 28 joint count and C-reactive protein; DMARD, disease modifying antirheumatic drug; EULAR, European League Against Rheumatism; RF, rheumatoid factor, SDAI, simplified disease activity index.